SNDX Head of R&d, CMO Botwood Nicholas A.J. Buys $311K of Stock
A key insider at Syndax Pharmaceuticals recently picked up shares of company stock.
Reviewed by automated data checks against the source filing. How we make and check alerts
Botwood Nicholas A.J., Head of R&D, CMO at Syndax Pharmaceuticals, Inc. ($SNDX), bought 22,515 shares at an average price of $13.82, worth about $311,157.30, on June 11, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SNDX is up 6.1% after 1 week, up 27.8% after 1 month and down 28.0% to date (from the $17.91 close on Jun 11, 2026).
SNDX
Syndax Pharmaceuticals, Inc.
Key Points
- Syndax Pharmaceuticals Head of R&D and CMO Nicholas Botwood acquired 22,515 shares of SNDX stock on June 11, 2026, at a price of $13.82 per share.
- The total value of this recent share purchase reached approximately $311,157, following a sequence of insider transactions by the executive.
- Wall Street maintains a strong buy consensus on the commercial-stage biotech firm, backed by a mean analyst price target of $37.55.
Get $SNDX trade alerts by text
We text you when insiders, Congress or big funds trade $SNDX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Syndax Pharmaceuticals, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. experienced recent insider trading activity as Head of R&D and Chief Medical Officer Nicholas Botwood picked up shares of company stock. On June 11, 2026, the executive bought 22,515 shares of SNDX at an average price of $13.82 per share. The transaction carried a total value of about $311,157. This buy adds to a busy period of transactions by the same officer, who also recorded other sales and purchases around mid-June 2026.
Syndax Stock Performance and Trading Range
The shares recently traded at $18.36. The stock has experienced a wide trading window over the past year, moving between a low of $12.99 and a high of $25.59. The company holds a market capitalization near $1.61 billion.
Recent Earnings and Financial Position
For its financial background, the commercial-stage biopharmaceutical firm reported revenue of $252.25 million with a revenue growth rate of 91.8%. The company is not currently profitable on a net basis, and it has no meaningful P/E ratio due to negative earnings per share of $2.51. Investors can look forward to the next scheduled earnings report from the company on November 2, 2026.
Wall Street Analyst Ratings and Price Targets
Analyst firms following the biotech company keep a positive view on its therapeutic pipeline. On October 13, 2026, HC Wainwright & Co. reiterated its buy rating on the stock with a price target of $38.00. Earlier, UBS maintained a buy rating while adjusting its target to $33.00 on August 21, 2026. JP Morgan kept an overweight rating on August 11, 2026, with a target price of $40.00. HC Wainwright & Co. also issued updates on August 5, 2026, and July 15, 2026, setting price targets of $38.00 and $40.00 respectively. Overall, the stock carries a strong buy recommendation key from a group of 11 analysts, with a mean price target resting at $37.55.
Inside the Pipeline at Syndax Pharmaceuticals
Syndax Pharmaceuticals focuses on developing innovative treatments for cancer. Its commercial lineup features Revuforj, a targeted therapy for certain types of acute leukemia, and Niktimvo, which treats chronic graft-versus-host disease. The company continues to test its core drug candidates across multiple clinical trials and expansion indications, keeping researchers and market watchers busy.
What to Watch at Syndax Pharmaceuticals, Inc.
Market participants will likely keep track of further Form 4 filings by company insiders to monitor executive sentiment. The next major operational milestone arrives with the company's earnings release scheduled for early November 2026, which will offer updated figures on commercial progress.
Related Filing Alerts
Source: Botwood Nicholas A.J.'s Form 4 filing on $SNDX (Jun 11, 2026). Find the original filing: SNDX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts